Gastrointestinal Events with Clopidogrel: A Nationwide Population-Based Cohort Study
- PDF / 354,987 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 42 Downloads / 214 Views
Department of Cardiology, Aarhus University Hospital, Skejby( Aarhus, Denmark; 2Research Center of Aging and Osteoporosis, Departments of Medicine and Diagnostics, Copenhagen University Hospital( Glostrup, Denmark; 3Faculty of Health Sciences, Copenhagen University( Copenhagen, Denmark; 4Medical Faculty, Aalborg University( Aalborg, Denmark.
BACKGROUND: Clopidogrel prevents cardiovascular events, but has been linked with adverse gastrointestinal (GI) complications, particularly bleeding events. OBJECTIVE: We aimed to investigate the risk of adverse GI events in patients treated with clopidogrel. DESIGN: A nationwide population-based cohort study based on linkage of three administrative registries in Denmark. PARTICIPANTS: All individuals who redeemed at least one prescription of clopidogrel from 1996 to 2008 were included as exposed subjects (n = 77,503). For each exposed subject, three matched controls were randomly selected from the background population (n = 232,510). ANALYSES: Follow-up began on January 1, 1996, and was censored on December 31, 2007, or if patients emigrated or died. The study endpoint was the occurrence of any gastritis, GI ulcer or bleeding. Analyses were adjusted for comorbidity and medication. RESULTS: Regardless of dose, adjusted odds ratios associating clopidogrel use with the study endpoint were statistically significant and followed a dose– response pattern. The crude absolute risk of GI events were: never users: 2.2 %;
Data Loading...
